Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for ...

Iovance Biotherapeutics has hired Corleen Roche as the biotechnology company's new chief financial officer, effective Aug. 6. Iovance on Tuesday said Roche, 59 years old, most recently served as ...

Detailed price information for Iovance Biotherapeutics Inc (IOVA-Q) from The Globe and Mail including charting and trades.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal ...

NXT007 leverages the Roche Group’s expertise in haemophilia A and bispecific antibody development. Our goal is to bring a next generation prophylactic to our portfolio, offering greater ...

A history of RocheWe explore the history of global pharmaceutical group Hoffmann-La Roche from where it first began, to its core structure and its focus for the future in personalised medicine ...

See the latest Roche Holding AG ADR stock price (RHHBY:PINX), related news, valuation, dividends and more to help you make your investing decisions.

Roche has revealed good results from a phase 2 trial of its oral BTK drug fenebrutinib in relapsing multiple sclerosis as it waits for phase 3 data.

But over time, I have found what works for me. My go-to is La Roche-Posay’s Anthelios Invisible Fluid. It’s lightweight, easy to wear, and fits well into my routine.

Natalie La Roche Pietri is the education reporter at WLRN. Before joining WLRN, Natalie interned at the Boston Globe on the Great Divide, a team dedicated to investigating race, class, and ...

The latest international Roche Holding AG news and views from Reuters - one of the world's largest news agencies ...